felodipine has been researched along with Hibernation, Myocardial in 2 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed at investigating contractile changes after hypoxia-reoxygenation and dobutamine challenge in superfused human atrial pectinate muscle to see whether high versus low stimulation rate during hypoxia might account for outcome differences compatible with the definition of an in vitro model of myocardial stunning and whether pretreatment with the dihydropyridine Ca2+ entry blocker felodipine might afford protection." | 9.08 | Felodipine protects human atrial muscle from hypoxia-reoxygenation dysfunction: a force-frequency relationship study in an in vitro model of stunning. ( Bernucci, P; Brancaccio, GL; Criniti, A; d'Amati, G; Dawodu, AA; Gallo, P; Gaudio, E; Iwashiro, K; Monti, F; Pannarale, L; Puddu, PE; Sinatra, R; Vetuschi, A, 1997) |
| "We aimed at investigating contractile changes after hypoxia-reoxygenation and dobutamine challenge in superfused human atrial pectinate muscle to see whether high versus low stimulation rate during hypoxia might account for outcome differences compatible with the definition of an in vitro model of myocardial stunning and whether pretreatment with the dihydropyridine Ca2+ entry blocker felodipine might afford protection." | 5.08 | Felodipine protects human atrial muscle from hypoxia-reoxygenation dysfunction: a force-frequency relationship study in an in vitro model of stunning. ( Bernucci, P; Brancaccio, GL; Criniti, A; d'Amati, G; Dawodu, AA; Gallo, P; Gaudio, E; Iwashiro, K; Monti, F; Pannarale, L; Puddu, PE; Sinatra, R; Vetuschi, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rose, J | 1 |
| Heusch, G | 1 |
| Iwashiro, K | 1 |
| Criniti, A | 1 |
| Sinatra, R | 1 |
| Dawodu, AA | 1 |
| d'Amati, G | 1 |
| Monti, F | 1 |
| Pannarale, L | 1 |
| Bernucci, P | 1 |
| Brancaccio, GL | 1 |
| Vetuschi, A | 1 |
| Gaudio, E | 1 |
| Gallo, P | 1 |
| Puddu, PE | 1 |
1 trial available for felodipine and Hibernation, Myocardial
| Article | Year |
|---|---|
Felodipine protects human atrial muscle from hypoxia-reoxygenation dysfunction: a force-frequency relationship study in an in vitro model of stunning.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Calcium Channel Blockers; Culture Techniques; | 1997 |
1 other study available for felodipine and Hibernation, Myocardial
| Article | Year |
|---|---|
Attenuation of regional myocardial stunning by felodipine.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Disease Models, Animal; Dog | 1996 |